Biotech News
Related news
FATEFate Therapeutics2026-10-12 11:00 EST
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
KURAKura Oncology2026-10-07 11:15 EST
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
REPLReplimune Group2026-10-01 20:01 EST
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
BTAIBioXcel2026-08-28 10:00 EST
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
SNDXSyndax Pharmaceuticals2026-10-15 20:01 EST
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
KURAKura Oncology2026-09-08 11:00 EST
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
SNDXSyndax Pharmaceuticals2026-09-01 11:00 EST
Syndax Announces Participation in September Investor Conferences
SNYSanofi2026-10-12 16:05 EST
Sanofi: Information concerning the total number of voting rights and shares – September 2026
FATEFate Therapeutics2026-09-16 11:00 EST
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
ELVNEnliven Therapeutics2026-10-06 20:05 EST
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
BioXcel
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
Recent company news
BTAIBioXcel2026-08-28 10:00 EST
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
BTAIBioXcel2026-05-28 11:00 EST
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
BTAIBioXcel2026-05-15 11:00 EST
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BTAIBioXcel2026-04-17 11:00 EST
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
BTAIBioXcel2026-04-08 11:00 EST
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Stock data
- Close
- 0.07 USD
- Market cap
- 36.74M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States